Race Oncology Statistics
Total Valuation
Race Oncology has a market cap or net worth of 106.46 million. The enterprise value is 94.47 million.
| Market Cap | 106.46M |
| Enterprise Value | 94.47M |
Important Dates
The next estimated earnings date is Monday, May 26, 2025.
| Earnings Date | May 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.44% |
| Shares Change (QoQ) | +16.82% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 120.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.74 |
| PB Ratio | 8.30 |
| P/TBV Ratio | 9.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.94 |
| EV / Sales | 28.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.59
| Current Ratio | 20.59 |
| Quick Ratio | 20.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.20% and return on invested capital (ROIC) is -24.99%.
| Return on Equity (ROE) | -37.20% |
| Return on Assets (ROA) | -24.05% |
| Return on Invested Capital (ROIC) | -24.99% |
| Return on Capital Employed (ROCE) | -39.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.86% in the last 52 weeks. The beta is 2.13, so Race Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 2.13 |
| 52-Week Price Change | -15.86% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 3,442 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Race Oncology had revenue of 3.25 million and -4.74 million in losses. Loss per share was -0.03.
| Revenue | 3.25M |
| Gross Profit | 2.54M |
| Operating Income | -5.09M |
| Pretax Income | -4.74M |
| Net Income | -4.74M |
| EBITDA | -4.92M |
| EBIT | -5.09M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 11.62 million in cash and n/a in debt, giving a net cash position of 11.62 million.
| Cash & Cash Equivalents | 11.62M |
| Total Debt | n/a |
| Net Cash | 11.62M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.82M |
| Book Value Per Share | 0.07 |
| Working Capital | 11.19M |
Cash Flow
| Operating Cash Flow | -507,661 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 78.13%, with operating and profit margins of -156.53% and -145.66%.
| Gross Margin | 78.13% |
| Operating Margin | -156.53% |
| Pretax Margin | -145.66% |
| Profit Margin | -145.66% |
| EBITDA Margin | -151.17% |
| EBIT Margin | -156.53% |
| FCF Margin | n/a |
Dividends & Yields
Race Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.44% |
| Shareholder Yield | -4.44% |
| Earnings Yield | -4.45% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Race Oncology has an Altman Z-Score of 145.21.
| Altman Z-Score | 145.21 |
| Piotroski F-Score | n/a |